



Conquering hepatitis C in our time

Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) notice posted to shareholders

Rehovot, Israel, 7 July 2005 - The Company has posted to shareholders a notice convening its AGM and an EGM. The AGM will take place the Company's offices, Kiryat Weizmann Science Park, Bldg 3, 3 Hasapir St, Ness Ziona 76100, Israel at 10a.m. (Israel Time) on 1 August 2005 and the EGM will follow at 4p.m. at the same venue on the same day.

At the AGM it is proposed that:

- the annual reports for the year ended 31 December 2004 be received;
- Kesselman & Kesselman be reappointed as the Company's auditors;
- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy and Jonathan Spicehandler be reappointed as Directors of the Company;
- Vered Shany and Ido Seltenreich be appointed as External Directors of the Company; and
- the Company's articles be amended.

At the EGM it is proposed that:

- the remuneration for non-Executive Directors be approved;
- the grant of options to William Kennedy and Jonathan Spicehandler be approve;
- the grant of options to Ben-Zion Weiner be approved;
- the annual fee of Michael Weiss and the remaining terms of remuneration of Michael Weiss including the grant of options;
- the Company's purchase of liability insurance be approved; and
- the indemnification to the Board members be approved

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer

Tel: +972 8 930 4440

Notes to Editors

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. Established in 1993, XTLbio became a public company in 2000 and its ordinary shares are listed on the Official List of the UK Listing Authority and are traded on the London Stock Exchange under the symbol XTL.